Preventative measures can reduce jawbone risk from osteoporosis drugs
The drugs, known as bisphosphonates, include Fosamax, Actonel, Boniva, Skelid, Didronel, Zometa, Aredia, and Bonefos. They are widely prescribed for osteoporosis and are also used to treat bone pain and other complications in cancer patients. Bisphosphonates increase bone density in the short run, but in the long run they may impair new bone formation. Scientists think this may reduce the jawbone’s capacity to heal after traumas such as dental extractions or implants.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online Plus (HHO+) to unlock expert-backed health insights, personalized tools, and exclusive resources to feel your best every day.
Here’s what you get with your HHO+ membership:
- Unlimited access to all Harvard Health Online content
- 4 expertly curated newsletters delivered monthly
- Customized website experience aligned to your health goals
- In-depth health guides on topics like sleep, exercise, and more
- Interactive features like videos and quizzes
- Members-only access to exclusive articles and resources
I’d like to subscribe to HHO+ for $4.99/month to access expert-backed content to help make smart, informed decisions about my well-being.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.